AXN 1901
Alternative Names: AXN-1901Latest Information Update: 04 Aug 2023
At a glance
- Originator Axceso Biopharma
- Class Antiparkinsonians; Phosphates
- Mechanism of Action SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 10 Jul 2023 Early research in Parkinson's disease in South Korea, prior to July 2023 (unspecified route) (Axceso biopharma pipeline, July 2023)
- 09 Jul 2020 Axceso Biopharma files for patents protection for Composition for preventing or treating Parkinson's disease containing O-cyclic phytosphingosine-1-phosphate in World (Axceso biopharma website, July 2023)
- 30 Sep 2019 Axceso Biopharma has patents protection for Composition for preventing or treating Parkinson's disease containing O-cyclic phytosphingosine-1-phosphate in South Korea (Axceso biopharma website, July 2023)